Compare Abeona Therapeutics Inc (ABEO) vs Vistra Corp (VST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vistra Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Vistra Corp trades at $152.14 (market cap $52.51B). The key difference: Vistra Corp is far larger — about 140.7× Abeona Therapeutics Inc's market cap, and Vistra Corp pays a 0.59% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | VST | |
|---|---|---|
Market Cap | $373.32M | $52.51B |
Sector | Health | Technology |
52-Week High | $7.23 | $217.92 |
52-Week Low | $4.17 | $134.71 |
Enterprise Value | $228.22M | $74.26B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Vistra Corp (VST) trades at $157.22, up 4.08% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but faces cash flow challenges. Revenue growth from $17.74B to $19.4B and improved net margins to 11.52% reflect operational strength, supported by AI-driven power demand catalysts and a $6.3B buyback program.
Outlook remains positive with 91% analyst buy ratings and a $230.50 price target, though technical resistance near $159 and volatile earnings pose near-term risks. Long-term growth is fueled by nuclear/renewable expansion, but investors should monitor execution on guidance and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
